Mode
Text Size
Log in / Sign up

Ovarian carcinoma

Part of Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Ovarian carcinoma

19 trials tracked for Ovarian carcinoma.

19Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 13 Phase 1 4 Other / NA 2
  1. Phase 2 A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors Completed
  2. Phase 2 Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer Completed
  3. Phase 2 MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma Completed
  4. Phase 2 Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma Completed
  5. Phase 2 Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer Completed
  6. Phase 2 Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) Completed
Show 13 more trials
  1. Phase 2 Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Completed
  2. Phase 2 Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma Completed
  3. Phase 2 Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies Completed
  4. Phase 2 Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer Completed
  5. Phase 2 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma Completed
  6. Phase 2 Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Completed
  7. Phase 2 DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed
  8. Phase 1 A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen Completed
  9. Phase 1 Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed
  10. Phase 1 Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. Completed
  11. Phase 1 A Trial Evaluating TG4050 in Ovarian Carcinoma. Completed
  12. N/A Clinical Outcomes for Offering Genetic Testing in a Tiered Approach Completed
  13. N/A EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

Immunohistochemical profiling helps differentiate synchronous primary breast invasive carcinoma from metastatic ovarian carcinoma
Oncology Sys. Review
Immunohistochemical profiling helps differentiate synchronous primary breast invasive carcinoma from metastatic ovarian carcinoma One woman diagnosed with two different types of cancer simultaneously
This case report and literature review describes a patient with concurrent primary breast cancer and metastatic high-grade serous ovarian ca…
A rare case reveals how one patient can have both breast and ovarian cancer at once, highlighting a complex diagnostic challenge.
Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer
Allergy & Immunology Sys. Review
Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer New immune targets offer hope for ovarian cancer patients
This narrative review synthesizes evidence on follicular T cell subsets, tertiary lymphoid structures, and other immune features in ovarian …
A review highlights new immune system features that could help doctors predict treatment success and find better ways to fight ovarian cance…
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
Infectious Disease Sys. Review
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Case report review of fertility-sparing surgery for ovarian borderline mucinous tumor with carcinosarcomatous mural nodule
Rheumatology Sys. Review
Case report review of fertility-sparing surgery for ovarian borderline mucinous tumor with carcinosarcomatous mural nodule A rare ovarian tumor diagnosis explained in a single patient case
This source is a case report review describing a 27-year-old female patient with an ovarian borderline mucinous tumor and carcinosarcomatous…
Doctors treated a 27-year-old woman with a rare ovarian tumor using fertility-sparing surgery and chemotherapy, with no signs of the cancer …
Ovarian cancer diagnoses decreased during COVID-19 pandemic years at a Swiss center
Oncology Cohort
Ovarian cancer diagnoses decreased during COVID-19 pandemic years at a Swiss center Lockdowns Didn't Hurt Ovarian Cancer Survival
This retrospective cohort study of 218 patients at Bern University Hospital found primary ovarian cancer diagnoses decreased in 2020 and 202…
When the world shut down in 2020, hospitals faced a scary reality.
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer
Oncology RCT
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer New Drug Combo Extends Survival for Tough Ovarian Cancer Cases
In a phase 3 randomised controlled trial of 381 patients with platinum-resistant ovarian cancer, relacorilant plus nab-paclitaxel significan…
This combination offers a new, simpler option for patients who have run out of standard treatments.
Residual disease after surgery linked to survival in low-grade serous ovarian cancer
Oncology Cohort
Residual disease after surgery linked to survival in low-grade serous ovarian cancer For This Ovarian Cancer, Surgery Is Everything—Chemo May Not Help
This observational retrospective study of 25 patients with low-grade serous ovarian cancer found that residual disease status after primary …
For a rare ovarian cancer, a new study suggests that the quality of surgery is the single most important factor for survival, challenging th…
STAT1 and IL-7 show diagnostic potential for ovarian carcinoma subtypes in cohort study
Allergy & Immunology Cohort
STAT1 and IL-7 show diagnostic potential for ovarian carcinoma subtypes in cohort study Two Tiny Signals Could Help Doctors Tell Apart Two Ovarian Cancers
A cohort study analyzed transcriptome data from 68 patients with high-grade and low-grade serous ovarian carcinoma.
Two tiny gene signals may help doctors distinguish between two ovarian cancer types when biopsy results are unclear, guiding the right treat…
Retrospective cohort study of 217 surgically treated borderline ovarian tumors in Southern Sweden compares conservative versus complete staging surgery
Oncology Cohort
Retrospective cohort study of 217 surgically treated borderline ovarian tumors in Southern Sweden compares conservative versus complete staging surgery A Gentler Surgery for Ovarian Tumors May Be Safer Than We Thought
This retrospective, population-based cohort review evaluated 217 patients with borderline ovarian tumors (BOT) in Southern Sweden.
A less invasive surgery for borderline ovarian tumors may be just as safe as the standard approach, offering fewer complications without har…
Chemotherapy in HGSOC patients modulates NK cell receptors and ligands, observational study finds
Allergy & Immunology Cohort
Chemotherapy in HGSOC patients modulates NK cell receptors and ligands, observational study finds Chemotherapy linked to immune system changes in ovarian cancer patients
An observational cohort study of 107 HGSOC patients and 50 healthy controls found chemotherapy was associated with modulation of NK cell rec…
Chemotherapy in ovarian cancer may restore natural killer cell markers to healthy levels and boost proteins that help immune cells fight tum…
vNOTES shows non-inferiority to laparoscopy for ovarian cystectomy in pilot trial
Oncology RCT
vNOTES shows non-inferiority to laparoscopy for ovarian cystectomy in pilot trial Can a gentler surgery remove ovarian cysts with less pain?
A pilot RCT of 64 patients with benign ovarian tumors compared vNOTES to conventional laparoscopy.
A gentler surgery that removes ovarian cysts through the vagina instead of the belly caused less pain after the operation, a small trial fou…